id,content,title,publisher,url,publishedAt,symbols,description
f69c1eb2-b848-3562-ad50-c3884dd59b30,"{'id': 'f69c1eb2-b848-3562-ad50-c3884dd59b30', 'contentType': 'STORY', 'title': 'All bark, no bite: Trump’s latest trade war turns into another TACO salad for Wall Street', 'description': '', 'summary': 'Markets actually improved on the latest surprise round of Trump tariffs.', 'pubDate': '2025-09-26T20:40:46Z', 'displayTime': '2025-09-26T20:40:46Z', 'isHosted': True, 'bypassModal': False, 'previewUrl': None, 'thumbnail': {'originalUrl': 'https://media.zenfs.com/en/fortune_175/6892e2182f33eaa0d1d9cbea51c4f8de', 'originalWidth': 2048, 'originalHeight': 1365, 'caption': 'Six months after “Liberation Day,” the story looks different.', 'resolutions': [{'url': 'https://s.yimg.com/uu/api/res/1.2/IhQ3r6JztlspYbp9uo0HZw--~B/aD0xMzY1O3c9MjA0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/fortune_175/6892e2182f33eaa0d1d9cbea51c4f8de', 'width': 2048, 'height': 1365, 'tag': 'original'}, {'url': 'https://s.yimg.com/uu/api/res/1.2/zGIXEswqTds0LTo6cgnfcw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/fortune_175/6892e2182f33eaa0d1d9cbea51c4f8de', 'width': 170, 'height': 128, 'tag': '170x128'}]}, 'provider': {'displayName': 'Fortune', 'url': 'http://fortune.com/'}, 'canonicalUrl': {'url': 'https://finance.yahoo.com/news/bark-no-bite-trump-latest-204046597.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'clickThroughUrl': {'url': 'https://finance.yahoo.com/news/bark-no-bite-trump-latest-204046597.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'metadata': {'editorsPick': False}, 'finance': {'premiumFinance': {'isPremiumNews': False, 'isPremiumFreeNews': False}}, 'storyline': None}",N/A,N/A,N/A,N/A,N/A,N/A
519fe78d-3ec2-3a6d-855f-91bf5582e643,"{'id': '519fe78d-3ec2-3a6d-855f-91bf5582e643', 'contentType': 'STORY', 'title': ""Indian drugmaker Divi's misses June-quarter profit view on weak US pricing"", 'description': '', 'summary': ""The Hyderabad-based company's consolidated net profit rose 26.7% to 5.45 billion rupees ($62 million) for the quarter ended June 30.  Indian generic drugmakers, which get a significant chunk of their revenue from the U.S., have been grappling with weak pricing amid stiff competition in the region.  Divi's, one of India's largest manufacturers of active pharmaceutical ingredients (API), has flagged pricing pressure and high competition in its generics business in global markets, adding that it aims to increase its market share by launching molecules as they get off patent."", 'pubDate': '2025-08-06T07:03:24Z', 'displayTime': '2025-08-06T07:03:24Z', 'isHosted': True, 'bypassModal': False, 'previewUrl': None, 'thumbnail': None, 'provider': {'displayName': 'Reuters', 'url': 'https://www.reuters.com/'}, 'canonicalUrl': {'url': 'https://sg.finance.yahoo.com/news/indian-drugmaker-divis-misses-june-070324642.html', 'site': 'finance', 'region': 'SG', 'lang': 'en-SG'}, 'clickThroughUrl': {'url': 'https://finance.yahoo.com/news/indian-drugmaker-divis-misses-june-070324642.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'metadata': {'editorsPick': False}, 'finance': {'premiumFinance': {'isPremiumNews': False, 'isPremiumFreeNews': False}}, 'storyline': None}",N/A,N/A,N/A,N/A,N/A,N/A
afedceb5-b757-3b8a-ab6b-f271c2e29c24,"{'id': 'afedceb5-b757-3b8a-ab6b-f271c2e29c24', 'contentType': 'STORY', 'title': ""Divi's Laboratories Ltd (BOM:532488) Q4 2025 Earnings Call Highlights: Strong Financial ..."", 'description': '', 'summary': ""Divi's Laboratories Ltd (BOM:532488) reports robust growth in income and profit, while navigating supply chain constraints and competitive pressures."", 'pubDate': '2025-05-20T15:01:52Z', 'displayTime': '2025-05-20T15:01:52Z', 'isHosted': True, 'bypassModal': False, 'previewUrl': None, 'thumbnail': None, 'provider': {'displayName': 'GuruFocus.com', 'url': 'http://www.gurufocus.com/'}, 'canonicalUrl': {'url': 'https://finance.yahoo.com/news/divis-laboratories-ltd-bom-532488-150152132.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'clickThroughUrl': {'url': 'https://finance.yahoo.com/news/divis-laboratories-ltd-bom-532488-150152132.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'metadata': {'editorsPick': False}, 'finance': {'premiumFinance': {'isPremiumNews': False, 'isPremiumFreeNews': False}}, 'storyline': None}",N/A,N/A,N/A,N/A,N/A,N/A
07d9a7ea-cfdc-311a-b3b1-8040bbcea579,"{'id': '07d9a7ea-cfdc-311a-b3b1-8040bbcea579', 'contentType': 'STORY', 'title': ""Divi's Laboratories Ltd (BOM:532488) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ..."", 'description': '', 'summary': ""Divi's Laboratories Ltd (BOM:532488) reports robust financial performance and strategic advancements amid industry challenges."", 'pubDate': '2025-02-09T01:00:30Z', 'displayTime': '2025-02-09T01:00:30Z', 'isHosted': True, 'bypassModal': False, 'previewUrl': None, 'thumbnail': None, 'provider': {'displayName': 'GuruFocus.com', 'url': 'http://www.gurufocus.com/'}, 'canonicalUrl': {'url': 'https://finance.yahoo.com/news/divis-laboratories-ltd-bom-532488-010030504.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'clickThroughUrl': {'url': 'https://finance.yahoo.com/news/divis-laboratories-ltd-bom-532488-010030504.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'metadata': {'editorsPick': False}, 'finance': {'premiumFinance': {'isPremiumNews': False, 'isPremiumFreeNews': False}}, 'storyline': None}",N/A,N/A,N/A,N/A,N/A,N/A
db8c2fac-5ca5-32e3-b181-f7a2b5a8ed93,"{'id': 'db8c2fac-5ca5-32e3-b181-f7a2b5a8ed93', 'contentType': 'STORY', 'title': ""India's Divi's Labs beats Q3 profit estimates on strong API demand; shares rise"", 'description': '', 'summary': ""India's Divi's Laboratories reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses on customised production of chemical compounds used in drugs, sending its shares higher.  The company's consolidated net profit jumped 64.5% to 5.89 billion rupees ($67.6 million) in the third quarter, slightly above analysts' estimates of 5.13 billion rupees, as per LSEG data.  Divi's is one of India's largest manufacturers of active pharmaceutical ingredients (API), key components of a drug that produce the intended therapeutic effects."", 'pubDate': '2025-02-03T08:14:36Z', 'displayTime': '2025-02-03T08:14:36Z', 'isHosted': True, 'bypassModal': False, 'previewUrl': None, 'thumbnail': None, 'provider': {'displayName': 'Reuters', 'url': 'https://www.reuters.com/'}, 'canonicalUrl': {'url': 'https://sg.finance.yahoo.com/news/indias-divis-labs-beats-q3-081436616.html', 'site': 'finance', 'region': 'SG', 'lang': 'en-SG'}, 'clickThroughUrl': {'url': 'https://finance.yahoo.com/news/indias-divis-labs-beats-q3-081436616.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'metadata': {'editorsPick': False}, 'finance': {'premiumFinance': {'isPremiumNews': False, 'isPremiumFreeNews': False}}, 'storyline': None}",N/A,N/A,N/A,N/A,N/A,N/A
7c10098c-7bd6-3c84-9504-d2ef1e93d445,"{'id': '7c10098c-7bd6-3c84-9504-d2ef1e93d445', 'contentType': 'STORY', 'title': ""Divi's Laboratories Ltd (BOM:532488) Q2 2025 Earnings Call Highlights: Navigating Growth Amidst ..."", 'description': '', 'summary': ""Discover how Divi's Laboratories Ltd (BOM:532488) is balancing significant revenue growth with pricing pressures and logistical hurdles in its latest earnings call."", 'pubDate': '2024-11-11T11:01:01Z', 'displayTime': '2024-11-11T11:01:01Z', 'isHosted': True, 'bypassModal': False, 'previewUrl': None, 'thumbnail': None, 'provider': {'displayName': 'GuruFocus.com', 'url': 'http://www.gurufocus.com/'}, 'canonicalUrl': {'url': 'https://finance.yahoo.com/news/divis-laboratories-ltd-bom-532488-110101374.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'clickThroughUrl': {'url': 'https://finance.yahoo.com/news/divis-laboratories-ltd-bom-532488-110101374.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'metadata': {'editorsPick': False}, 'finance': {'premiumFinance': {'isPremiumNews': False, 'isPremiumFreeNews': False}}, 'storyline': None}",N/A,N/A,N/A,N/A,N/A,N/A
